ViroStatics is a privately held small pharmaceutical company dedicated to the discovery and the development of novel compounds for a multifaceted treatment of cancers and viral diseases, focusing on novel, selective, host cell kinase targeted inhibitors and inherently hindering the oncogene Myc.

The Team and Advisors combines scientific, business, legal, and technology expertise, spanning from translational science through preclinical and clinical drug development.

ViroStatics intends to license its compounds at the preclinical stage, with a patent protection to be extended until 2043.


Clinical Candidate Myrtleciclib
With a unique mechanism of action (blocking Myc ensuring selective, non-competitive CDK9/6/4 inhibition) Myrtleciclib exerts anti-proliferative activity against a broad spectrum of cancers, superior to comparators, and induces apoptosis and cell death, selectively on cancer cells. Learn more

Respiratory Viruses

ViroStatics is an independent contract testing laboratory specialized in the analysis of respiratory viruses such as SARS-CoV-2 and flu.

ViroStatics has developed a bioaerosol system in order to test nebulised drug treatments, inhalers, disinfectants or devices for virucidal activity in a state-of-the-art Biosafety Level 3 facility, according to the US CDC guidelines to identify countermeasures to minimise risk of infection.

June 27, 2023

ViroStatics announces the publication of a peer-reviewed article titled “SARS-CoV-2 Inactivation in Aerosol by Means of Radiated Microwaves”, Viruses

Read more…

February 28, 2023

28 FEBRUARY is Rare Disease Day.  ViroStatics is committed to discover and develop innovative drugs  for the treatment of aggressive cancers

Read more…

November 10, 2022

ViroStatics announces the publication of a peer-reviewed article titled “Synergistic drug combinations designed to fully suppress SARS-CoV-2 in the lung of COVID-19 patients”, PLOS ONE

Read more…

Developing Novel Compounds Targeting Cancers and Viruses

The Company has developed a robust pipeline of proprietary compounds to distinguish themselves from the competition through their unique kinase selectivity, efficacy and safety profiles.

Consistent with its well defined mechanism of action, ViroStatics’ lead compound has a good toxicity profile while exerting potent activity in preclinical models against most aggressive cancers with high unmet need such as mesothelioma, recurring metastatic breast cancer and highly malignant lymphoma.


ViroStatics awarded with H2020 Seal of Excellence

25 November 2020

“TOSCA” project proposal, aiming at reaching clinical readiness for VS2-370, a novel oral CDK4/6/9 inhibitor developed for the treatment of aggressive tumors (breast, lung, pancreas, haemato-oncology), for out-licensing or M&A with a Pharmaceutical Company, has been judged as a high quality proposal following highly competitive evaluation process by an international panel of independent experts and has been therefore awarded with the SEAL OF EXCELLENCE within the Horizon 2020’s SME instrument Phase 2 call H2020-EIC-SMEInst-2018-2020. Horizon 2020 is the biggest EU Research and Innovation programme ever for breakthroughs, discoveries and world-firsts by taking great ideas from the lab to the market.

ViroStatics among the best Italy-based Pharmaceutical companies

7 June 2021

ViroStatics among the best Italy-based Pharmaceutical companies Best

Companies were selected across the size spectrum from cutting edge startups to established brands. Startups and companies listed were chosen for exceptional performance in one of these categories:

Innovation  –  Growth  –  Management  –  Societal impact